Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Aug 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-08-05

Reporting Person: Stanker James H (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-05	Common Stock	M	7601	—	Acquired	51712	Direct
2022-08-05	Common Stock	F	2462	$3.17	Disposed	49250	Direct

Footnotes

F1: Vesting of time-based restricted shares.